Presymptomatic genetic testing for neurodegenerative diseases can help patients make effective treatment decisions, but the medical profession needs to ensure that the increasing use of the tests is done responsibly.
A recent journal article calls for a public policy that would require physician-researchers to demonstrate the absence of undue influence or coercion on informed consent.